Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 295

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand

WANG, B, NICHOL, J, SULLIVAN, J·2004·Clinical Pharmacology & Therapeutics

Abstract

OBJECTIVE: The objective of this study was to evaluate the tolerability, pharmacodynamics, and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand, after a single intravenous or subcutaneous injection in healthy subjects. METHODS: This was a first-in-human randomized, double-blind, placebo-controlled study with 48 subjects. Six subjects in each cohort were sequentially randomized in a 2:1 ratio to receive a single injection of AMG 531 or placebo. The dose ranges investigated were 0.3 to 10.0 microg/kg and 0.1 to 2.0 microg/kg via the intravenous and subcutaneous dosing routes, respectively. The pharmacodynamic response of AMG 531 was measured as the elevation in platelet counts. AMG 531 serum levels were determined by use of a validated enzyme-linked immunosorbent assay. RESULTS: Single intravenous or subcutaneous administration of AMG 531 induced a dose-dependent increase in platelet count in healthy subjects, with peak platelet count being achieved on days 12 to 16. The highest intravenous dose, 10.0 microg/kg, caused a nearly 6-fold increase in platelet count. The maximum increase for this cohort occurred on day 15, and the mean platelet count was 1380 x 10(9)/L (range, 923-1790 x 10(9)/L). Of 8 subjects receiving the 2.0-microg/kg subcutaneous dose, 6 had peak platelet levels that were double the baseline value. Platelet count was elevated to a similar extent after single intravenous or subcutaneous administration of AMG 531 at the same dose level (1.0 microg/kg), even though the subcutaneous serum levels were barely detectable. Platelet counts were close to the baseline value by day 28. After a single intravenous administration, the pharmacokinetics of AMG 531 was nonlinear in the 0.3- to 10.0-microg/kg dose range. Most AMG 531 serum levels fell below the assay's lower quantitation limit of 18 pg/mL after a single subcutaneous dose. There were no serious or life-threatening adverse events reported in this study. The most frequently reported events were mild to moderate headache and sore throat. CONCLUSION: AMG 531 was well tolerated in this study and was effective at raising platelet counts in healthy volunteers after single intravenous or subcutaneous administration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clpt.2004.08.010

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 295

Metadata

Authors
WANG, B., NICHOL, J., & SULLIVAN, J.
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
2004-12
Volume
76
Issue
6
Pages
628-638
ISSN
0009-9236 (ISSN-L)
OpenAlex
W2139745353
Cited by
295
References
10
FWCI
6.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. https://app.cochat.ai/papers/10.1016/j.clpt.2004.08.010
The paper
WANG, B., NICHOL, J., & SULLIVAN, J. (2004). Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/j.clpt.2004.08.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.